Jazz Pharmaceuticals Announces Acquisition of Cavion
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
Neuroscientists at Emory University Terminated Following Scrutiny of Chinese Funding Ties
Emory University in Georgia fired a husband and wife neuroscience research team after they were accused of failing to disclose ties to China that included financial funding.
Infuse storytelling with imagination and light up the brain
Our brains are hard-wired to receive information primarily through storytelling. The more imaginative, the better. Imagination is a powerful tool.
J&J prices ketamine-like depression treatment at $590-$885 for two doses
Johnson & Johnson said the company’s new nasal spray depression treatment Spravato will be priced at $590 for a 56-milligram dose and $885 for an 84-milligram dosage.
Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.
Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
7 Biotech Trends to Look Out for in 2019
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio
Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.
Mental health crisis could cost the world $16 trillion by 2030
Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.
Impatient patients turn to online ‘buyers club’ for new drugs
Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!